Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme’s Risky Pipeline Isn’t A Value Driver In The Sanofi Deal

You may also be interested in...



Sanofi/Genzyme And Isis Submit Kynamro For Lowering Cholesterol

It’s been a long haul, but Sanofi’s Genzyme business unit and Isis have submitted their NDA for a drug that helps lower cholesterol levels in high-risk patients with a rare genetic cardiovascular disease that doesn’t respond well to statins.

After The Patent Cliff, "New" Sanofi Will Deliver Steady, Modest, Growth

Sanofi is through the worst of its patent cliff and can deliver sales growth of at least 5% per year, on average, between 2012 and 2015, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts. And if 5% is a far cry from the double-digit pharma growth of yesteryear, investors may take heart from higher earnings growth, thanks in large part to an additional €2 billion ($2.8 billion) worth of cost savings and pared down R&D spend – and the promise of a higher dividend.

After The Patent Cliff, "New" Sanofi Will Deliver Steady, Modest, Growth

Sanofi is through the worst of its patent cliff and can deliver sales growth of at least 5% per year, on average, between 2012 and 2015, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts. And if 5% is a far cry from the double-digit pharma growth of yesteryear, investors may take heart from higher earnings growth, thanks in large part to an additional €2 billion ($2.8 billion) worth of cost savings and pared down R&D spend – and the promise of a higher dividend.

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel